Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab. (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s599. https://doi.org/10.25251/y4a30r91